Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1073 • ACR Convergence 2021
In Favor of the Subspecialty Clinic Model for Rheumatoid Arthritis
Jasmine Thai¹, Roshan Patel¹, Yeohan Song¹ and Sheryl Mascarenhas², ¹Ohio State University, Columbus, OH, ²Ohio State University Hospital, Columbus, OH
Background/Purpose: The Subspecialty Clinic Model (SCM) which seeks to allow for collaborative care and services by stratifying patients with a particular disease or need to…
Abstract Number: 1200 • ACR Convergence 2021
Predicting Progression to RA in Patients with Seropositive Arthralgia
Aine Gorman¹, Keelin Flynn², Matthew Turk¹, Candice Low³, Kieran Murray⁴, Carl Orr⁵, Phil Gallagher⁵, Lorna Freeman², Edel Meaney², Eamonn Molloy⁶, Lorraine O Neill⁷, Ursula Fearon⁸ and Douglas Veale⁹, ¹St Vincents Hospital, Dublin, Ireland, ²The Centre for Arthritis and Rheumatic Disease, EULAR Centre of Excellence, St. Vincent’s University Hospital and University College Dublin, Ireland, Dublin, Ireland, ³St. Vincent's University Hospital, Dublin, Ireland, ⁴Saint Vincent's University Hospital, Dublin, Ireland, ⁵St Vincent's Hospital, Dublin, Ireland, ⁶St Vincent's Healthcare Group, Dublin, Ireland, ⁷St. Vincent's Hospital, Dublin, Ireland, ⁸Trinity College Dublin, Dublin, Ireland, ⁹University College Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory condition often associated with joint destruction, disability, and reduced life expectancy. Before RA diagnosis, some patients may…
Abstract Number: 1216 • ACR Convergence 2021
Evidence of a Tendency for Localized Recurrence of Arthritis in Rheumatoid Arthritis Patients
Sascha Heckert¹, Sytske Anne Bergstra¹, Xanthe Matthijssen¹, Yvonne Goekoop-Ruiterman², Faouzia Fodili³, Saskia ten Wolde⁴, Cornelia F. Allaart¹ and Tom WJ Huizinga¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²HagaZiekenhuis, The Hague, Netherlands, ³Stichting ReumaZorg ZWN, Roosendaal, Netherlands, ⁴Spaarne Gasthuis, Haarlem, Netherlands
Background/Purpose: Local inflammation may cause synovial fibroblasts to become sensitized, resulting in higher susceptibility to arthritis. Longitudinal assessment of joint involvement in rheumatoid arthritis (RA)…
Abstract Number: 1232 • ACR Convergence 2021
Synovial Tissue Lymphoid Aggregates Are Associated with Response to Rituximab Therapy in Rheumatoid Arthritis Patients
Matthew Turk¹, Candice Low², Carl Orr³, Richard Conway⁴, Kieran Murray⁵, Ursula Fearon⁶ and Douglas Veale⁷, ¹St. Vincents University Hospital, Dublin, Ireland, ²St. Vincent's University Hospital, Dublin, Ireland, ³St Vincent's Hospital, Dublin, Ireland, ⁴St. James's University Hospital, Dublin, Ireland, ⁵Saint Vincent's University Hospital, Dublin, Ireland, ⁶Trinity College Dublin, Dublin, Ireland, ⁷University College Dublin, Dublin, Ireland
Background/Purpose: Activated B lymphocytes and plasma cells are implicated in the pathogenesis of rheumatoid arthritis (RA). The anti-CD20 monoclonal antibody therapy (Rituximab) is an effective…
Abstract Number: 1248 • ACR Convergence 2021
Adjusted Analyses of the Benefits of Autoantibody Enrichment on Efficacy Outcomes in Early RA, from a Pooled Analysis of 4 Abatacept RCTs
Janet Pope¹, Sang Hee Park², Mirko Fillbrunn³, Karissa Lozenski², Vadim Khaychuk², Kaleb Michaud⁴, James Signorovitch³, Henry Lane³, Ha Nguyen³ and Philip Conaghan⁵, ¹University of Western Ontario, London, ON, Canada, ²Bristol Myers Squibb, Princeton, NJ, ³Analysis Group, Inc., Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Previous studies have found differential treatment efficacy of abatacept (ABA) for the treatment of RA based on biomarker-seropositivity.1-4 An earlier study found a differential…
Abstract Number: 1445 • ACR Convergence 2021
Association Between Baseline Use of Rituximab and COVID-19 Outcomes in Patients with Rheumatoid Arthritis (RA)
Namrata Singh¹, Chen Hu², Vithal Madhira², Kate Fitzgerald², Timothy Bergquist³, Kayte Anderson², Amy Olex⁴, Rena Patel⁵ and Jasvinder Singh⁶, ¹University of Washington, Bellevue, WA, ²Johns Hopkins, Baltimore, MD, ³Sage Bionetworks, Seattle, WA, ⁴Virginia Commonwealth University, Richmond, VA, ⁵UW, Seattle, WA, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with Rheumatoid arthritis (RA) are at a potentially increased risk of SARS-CoV-2 infection, and immunosuppressive or biologic drugs used to treat RA might…
Abstract Number: 1645 • ACR Convergence 2021
Elevations in Adipocytokines and Mortality in Rheumatoid Arthritis
Joshua Baker¹, Bryant England², Michael George¹, Katherine Wysham³, Gail Kerr⁴, Andreas Reimold⁵, Paul Monach⁶, Gary Kunkel⁷, Brian Sauer⁷, Bartlett Hamilton⁸, Carlos Hunter², Michael Duryee², Geoffrey Thiele² and Ted Mikuls², ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁵University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ⁶Brigham and Women's Hospital, Boston, MA, ⁷University of Utah, Salt Lake City, UT, ⁸University of Nebraska, Omaha, NE
Background/Purpose: Adipokines are metabolic regulators and are associated with adverse outcomes in chronic conditions and among older adults. Elevations in one adipokine, adiponectin, have been…
Abstract Number: 1663 • ACR Convergence 2021
The Influence of Comorbidity on Mortality in Patients with Rheumatoid Arthritis 1980-2015: A Longitudinal Population-based Study in Western Australia
Khalid Almutairi¹, Johannes Nossent¹, David Preen¹, Helen Keen² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Australia, ²University of Western Australia, Daglish, Australia, ³University of Western Australia, Nedlands, Perth, Australia
Background/Purpose: Rheumatoid arthritis (RA) contributes to excess morbidity and mortality in RA patients compared with the general population. In Australia, there is a paucity of…
Abstract Number: 1679 • ACR Convergence 2021
Effectiveness and Safety of Tocilizumab SC Every 10 Days in Patients with Rheumatoid Arthritis Who Previously Used Tocilizumab EV During the COVID 19 Pandemic at the Hospital Docente Padre Billini, Dominican Republic
Teresandris Polanco Mora, Jennifer Santana Peralta de Heyaime, Angelo Cornelio Vasquez, Yamilet Cruz, Edral Rodriguez, Tirso Valdez Lorie, Roberto Munoz and Rafael Alba Feriz, Hospital Docente Padre Billini, Santo Domingo, Dominican Republic
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease systemic, with a prevalence 0.5 - 1% of the population, with predilection for the female sex. (1)…
Abstract Number: 1695 • ACR Convergence 2021
Erythrocyte Methotrexate Polyglutamates Are Substantially Higher After Subcutaneous Methotrexate Treatment in Rheumatoid Arthritis Patients in the First Months of Treatment
Renske Hebing¹, Sohaila Mahmoud¹, Marry Lin², Ittai Muller², Sandra Heil³, Willem Lems⁴, Mike Nurmohamed⁵, Robert de Jonge² and Gerrit Jansen², ¹Reade, Amsterdam, Netherlands, ²AmsterdamUMC, Amsterdam, Netherlands, ³ErasmusMC, Rotterdam, Netherlands, ⁴VUmc, Amsterdam, Netherlands, ⁵Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands
Background/Purpose: Optimal dosing of methotrexate (MTX) for individual rheumatoid arthritis (RA) patients to achieve adequate disease control remains challenging. Assessment of erythrocyte MTX-polyglutamates (PGs) levels…
Abstract Number: 1722 • ACR Convergence 2021
Risk of Pre-eclampsia and Impact of Disease Activity and Anti-rheumatic Treatment in Women with Rheumatoid Arthritis, Axial Spondylarthritis, and Psoriatic Arthritis – A Collaborative Matched Cohort Study from Sweden and Denmark
Anne Emilie Secher¹, Karin Hellgren², Bente Glintborg³, Ane Rom⁴, Merete Hetland⁵ and Fredrik Granath², ¹COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Frederiksberg, Denmark, ²Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ³COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Glostrup, Denmark, ⁴The Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Denmark, ⁵DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Pre-eclampsia is a pregnancy-related syndrome with potentially fatal outcomes. In RA, high disease activity has been associated to adverse pregnancy outcomes such as preterm…
Abstract Number: 1939 • ACR Convergence 2021
Risk of Cardiovascular Outcomes in Patients Treated with Tofacitinib: First Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study
Farzin Khosrow-Khavar, Seoyoung Kim, Hemin Lee, Su Been Lee and Rishi Desai, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Recent reports from a post-marketing safety trial, “ORAL Surveillance”, indicated an increased risk of cardiovascular (CV) outcomes in RA patients treated with tofacitinib. Thus,…
Abstract Number: 0026 • ACR Convergence 2021
Synovial Fibroblasts Acquire a Proinflammatory and Destructive Phenotype After Exposure to αS1-Casein (CSN1S1)
Nadine Honke¹, Tim Appel¹, Matthias Schneider² and Georg Pongratz³, ¹Department of Rheumatology, Hiller Research Center Rheumatology, University Hospital Düsseldorf, Germany (* contributed equally), Düsseldorf, Germany, ²Policlinic & Hiller Research Unit Rheumatology, UKD, Heinrich-Heine University, Düsseldorf, Germany, ³Polyclinic and Functional Area for Rheumatology & Hiller Research Center Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany
Background/Purpose: The milk protein αS1-Casein (CSN1S1) was described to be overexpressed in synovial tissue of patients with rheumatoid arthritis (RA) and osteoarthritis (OA). Recently we…
Abstract Number: 0042 • ACR Convergence 2021
High-throughput Testing for Modified-protein Antibodies in Patients Diagnosed with “Seronegative” Rheumatoid Arthritis
Michael Richter¹, Hari Krishnamurthy², Sylvia Posso³, Jeffrey Carlin⁴ and Jane Buckner³, ¹University of Washington, Mercer Island, WA, ²Vibrant Sciences, San Carlos, CA, ³Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁴Virginia Mason Medical Center, Seattle, WA
Background/Purpose: Antibodies to citrullinated and other modified proteins play a critical role in the pathogenesis of rheumatoid arthritis (RA). The prevalence and degree of multi-site…
Abstract Number: 0146 • ACR Convergence 2021
Improving Medication Toxicity Lab Monitoring During the COVID-19 Pandemic
Akrithi Udupa¹, Catherine Sims², Poorva Apte², Megan Milne², Isaac Smith¹, D Ryan Anderson¹, Mithu Maheswaranathan², Jayanth Doss² and David Leverenz², ¹Duke University Hospital, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: The COVID-19 pandemic led to the rapid implementation of telehealth in rheumatology with unknown implications for medication toxicity lab monitoring. The purpose of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.